Male breast cancer is a
rare disease. In Tunisia, it represents 1% of all breast cancers and 1.6% of
Male neoplasia. This work is a retrospective study about 5 male patients with
breast cancer, treated in the department of medical oncology at Fattouma
Bourguiba University Hospital of Monastir (Tunisia) during a period of 3 years
from March 2013 to March 2016. Results showed that: invasive ductual carcinoma was the histological
type found in all cases; the
Her 2 neu was not overexpressed in all cases; hormone receptors were positive in all patients.
Two patients had a locally advanced disease. Two patients were diagnosed with
metastatic disease; pulmonary and bone metastases. Three patients who were
diagnosed with no metastatic disease have had a mastectomy with Axillary lymph
node dissection. Adjuvant chemotherapy was administered in two patients. Loco
regional radiotherapy was performed in three patients. Tamoxifen-based hormone
therapy was administered in three patients. Two patients were treated with palliative
chemotherapy. One patient received two lines of chemotherapy with a global
survival of 16 months, while the other received only one line of palliative
chemotherapy with a global survival of 2 months. One patient received
palliative hormone therapy type Tamoxifen with progression free survival of 7
months. Three patients who received curative treatments are in remission of
their disease. To conclude male breast cancer is a rare disease with multiple
and varied risk factors. It is similar in its clinical, histological and
prognostic characteristics to breast cancer in women but also has different
Cite this paper
Sonia, Z. , Wiem, K. , Ibtissem, A. , Salem, A. B. , Salma, A. , Hayfa, B. , Olfa, Z. , Houda, M. , Raja, F. , Hayet, L. and Amira, D. (2017). Male Breast Cancer: Case Studies and Literature Review. Open Access Library Journal, 4, e3695. doi: http://dx.doi.org/10.4236/oalib.1103695.
Oger, A.S., Boukerrou, M., Cutuli, B., Campion, L., Rousseau, E., Bussières, E., et al. (2015) Male Breast: An Epidemiological, Diagnostic and Therapeutic Approach: A Retrospective Multicenter Study of 95 Cases. Gynécologie Obstétrique & Fertilité, 43, 290-296.
Masci, G., Caruso, M., Caruso, F., Salvini, P., Carnaghi, C., Giordano, L., et al. (2015) Clinicopathological and Immunohistochemical Characteristics in Male Breast Cancer: A Retrospective Case Series. Oncologist, 20, 586-592.
Thomas, D.B., Jimenez, L.M., McTiernan, A., Rosenblatt, K., Stalsberg, H., Stemhagen, A., et al. (1992) Breast Cancer in Men: Risk Factors with Hormonal Implications. American Journal of Epidemiology, 135, 734-748.
Brinton, L.A., Key, T.J., Kolonel, L.N., Michels, K.B., Sesso, H.D., Ursin, G., et al. (2015) Prediagnostic Sex Steroid Hormones in Relation to Male Breast Cancer Risk. Journal of Clinical Oncology, 33, 2041-2050.
Brinton, L.A., Cook, M.B., McCormack, V., Johnson, K.C., Olsson, H., Casagrande, J.T., et al. (2014) Anthropometric and Hormonal Risk Factors for Male Breast Cancer: Male Breast Cancer Pooling Project Results. Journal of the National Cancer Institute, 106, djt465.
Sverdlov, R.S., Barshack, I., Bar Sade, R.B., Baruch, R.G., Hirsh-Yehezkel, G., Dagan, E., et al. (2000) Genetic Analyses of Male Breast Cancer in Israel. Genetic Testing, 4, 313-317.
Ottini, L., Masala, G., D’Amico, C., Mancini, B., Saieva, C., Aceto, G., et al. (2003) BRCA1 and BRCA2 Mutation Status and Tumor Characteristics in Male Breast Cancer: A Population-Based Study in Italy. Cancer Research, 63, 342-347.
Basham, V.M., Lipscombe, J.M., Ward, J.M., Gayther, S.A., Ponder, B.A., Easton, D.F., et al. (2002) BRCA1 and BRCA2 Mutations in a Population-Based Study of Male Breast Cancer. Breast Cancer Research, 4, R2.
Friedman, L.S., Gayther, S.A., Kurosaki, T., Gordon, D., Noble, B., Casey, G., et al. (1997) Mutation Analysis of BRCA1 and BRCA2 in a Male Breast Cancer Population. The American Journal of Human Genetics, 60, 313-319.
Kwiatkowska, E., Teresiak, M., Filas, V., Karczewska, A., Breborowicz, D. and Mackiewicz, A. (2003) BRCA2 Mutations and Androgen Receptor Expression as Independent Predictors of Outcome of Male Breast Cancer Patients. Clinical Cancer Research, 9, 4452-4459.
Jordan, V.C. (2009) A Century of Deciphering the Control Mechanisms of Sex Steroid Action in Breast and Prostate Cancer: The Origins of Targeted Therapy and Chemoprevention. Cancer Research, 69, 1243-1254.
Escudie, P., Monteil-Onteniente, S., Gladieff, L., Feillel, V., Guimbaud, R., Favre, G., et al. (2010) A Novel Germline CHEK2 Deletion Truncating the Kinase Domain Identified in a French Family with High-Risk of Breast/Ovarian Cancer. Breast Cancer Research and Treatment, 120, 267-270.
Korde, L.A., Zujewski, J.A., Kamin, L., Giordano, S., Domchek, S., Anderson, W.F., et al. (2010) Multidisciplinary Meeting on Male Breast Cancer: Summary and Research Recommendations. Journal of Clinical Oncology, 28, 2114-2122.
Villeneuve, S., Cyr, D., Lynge, E., Orsi, L., Sabroe, S., Merletti, F., et al. (2010) Occupation and Occupational Exposure to Endocrine Disrupting Chemicals in Male Breast Cancer: A Case-Control Study in Europe. Occupational and Environmental Medicine, 67, 837-844.
Cook, M.B., Guenel, P., Gapstur, S.M., van den Brandt, P.A., Michels, K.B., Casagrande, J.T., et al. (2015) Tobacco and Alcohol in Relation to Male Breast Cancer: An Analysis of the Male Breast Cancer Pooling Project Consortium. Cancer Epidemiology, Biomarkers & Prevention, 24, 520-531.
Laabadi, K., Jayi, S., Alaoui, F.F., Bouguern, H., Chaara, H., Melhouf, M., et al. (2013) Male Breast Cancer about 6 Cases. The Pan African Medical Journal, 16, 70.
Hirose, Y., Sasa, M., Bando, Y., Hirose, T., Morimoto, T., Kurokawa, Y., et al. (2007) Bilateral Male Breast Cancer with Male Potential Hypogonadism. World Journal of Surgical Oncology, 5, 60.
Contractor, K.B., Kaur, K., Rodrigues, G.S., Kulkarni, D.M. and Singhal, H. (2008) Male Breast Cancer: Is the Scenario Changing? Hypogonadism. World Journal of Surgical Oncology, 6, 58.
Ly, D., Forman, D., Ferlay, J., Brinton, L.A. and Cook, M.B. (2013) An International Comparison of Male and Female Breast Cancer Incidence Rates. International Journal of Cancer, 132, 1918-1926.
Sipetic-Grujicic, S.B., Murtezani, Z.H., Neskovic-Konstatinovic, Z.B., Marinkovic, J.M., Kovcin, V.N., Andric, Z.G., et al. (2014) Multivariate Analysis of Prognostic Factors in Male Breast Cancer in Serbia. Asian Pacific Journal of Cancer Prevention, 15, 3233-3238.
Goss, P.E., Reid, C., Pintilie, M., Lim, R. and Miller, N. (1999) Male Breast Carcinoma: A Review of 229 Patients Who Presented to the Princess Margaret Hospital during 40 Years 1955-1996. Cancer, 85, 629-639.
Evans, G.F., Anthony, T., Turnage, S.D., Levyk, R., Aminkhan, R.H., et al. (2001) The Diagnostic Accuracy of Mammography in the Evaluation of Male Breast Disease. The American Journal of Surgery, 181, 96-100.
Tunon de Lara, C., Goudy, G., Mac Grogan, G., Durand, M., Dilhuydy, J.M., Avril, A., et al. (2008) Male Breast Cancer about 52 Cases Treated at the Institut Bergonié de Bordeaux between 1980 and 2004. Gynécologie Obstétrique & Fertilité, 36, 386- 394.
Chen, L., Chantra, P.K., Larsen, L.H., Barton, P., Rohitopakarn, M., Zhu, E.Q., et al. (2006) Imaging Characteristics of Malignant Lesions of the Male Breast. Radiographics, 26, 993-1006.
Hittmair, A.P., Lininger, R.A. and Tavassoli, F.A. (1998) Ductal Carcinoma in Situ (DCIS) in the Male Breast: A Morphologic Study of 84 Cases of Pure DCIS and 30 Cases of DCIS Associated with Invasive Carcinoma—A Preliminary Report. Cancer, 83, 2139-2149.
Namba, N., Hiraki, A., Tabata, M., Kiura, K., Ueoka, H., Yoshino, T., et al. (2002) Axillary Metastasis as the First Manifestation of Occult Breast Cancer in a Man: A Case Report. Anticancer Research, 22, 3611-3613.
Basuyau, J.P., Blanc-Vincent, M.P., Bidart, J.M., Daver, A., Deneux, L., Eche, N., et al. (2000) Standards, Options et Recommandations (SOR): Tumor Markers of Breast Cancer. Bulletin du Cancer, 87, 723-737.
Mauriac, L., Luporsi, E., Cutuli, B., Fourquet, A., Garbay, J.R., Giard, S., et al. (2003) Standards, Options and Recommendations for the Management of Patients with Infiltrating non Metastatic Breast Cancer (2nd Edition, 2001)—Summary Version. Gynécologie Obstétrique & Fertilité, 31, 284-315.
The American Society of Clinical Oncology (1998) Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer. Journal of Clinical Oncology, 16, 793-795.
Agrawal, A., Ayantunde, A.A., Rampaul, R. and Robertson, J.F. (2007) Male Breast Cancer: A Review of Clinical Management. Breast Cancer Research and Treatment, 103, 11-21.
Wick, M.R., Sayadi, H., Ritter, J.H., Hill, D.A., Reddy, V.B. and Gattuso, P. (1999) Low-Stage Carcinoma of the Male Breast. A Histologic, Immunohistochemical, and Flow Cytometric Comparison with Localized Female Breast Carcinoma. American Journal of Clinical Pathology, 111, 59-69.
Ottini, L., Rizzolo, P., Zanna, I., Falchetti, M., Masala, G., Ceccarelli, K., et al. (2009) BRCA1/BRCA2 Mutation Status and Clinical-Pathologic Features of 108 Male Breast Cancer Cases from Tuscany: A Population-Based Study in Central Italy. Breast Cancer Research and Treatment, 116, 577-586.
Cho, J., Han, W., Ko, E., Lee, J.W., Jung, S.Y., Kim, E.K., et al. (2007) The Clinical and Histopathological Characteristics of Male Breast Cancer Patient. Journal of Breast Cancer, 10, 211-216.
Cloyd, J.M., Hernandez-Boussard, T. and Wapnir, I.L. (2013) Outcomes of Partial Mastectomy in Male Breast Cancer Patients: Analysis of SEER, 1983-2009. Annals of Surgical Oncology, 20, 1545-1550.
Cutuli, B., Dilhuydy, J.M., De Lafontan, B., Berlie, J., Lacroze, M., Lesaunier, F., et al. (1997) Ductal Carcinoma in Situ of the Male Breast. Analysis of 31 Cases. European Journal of Cancer, 33, 35-38.
Harlan, L.C., Zujewski, J.A., Goodman, M.T. and Stevens, J.L. (2010) Breast Cancer in Men in the United States: A Population-Based Study of Diagnosis, Treatment, and Survival. Cancer, 116, 3558-3568.
Cutuli, B., Lacroze, M., Dilhuydy, J.M., Velten, M., De Lafontan, B., Marchal, C., et al. (1995) Male Breast Cancer: Results of the Treatments and Prognostic Factors in 397 Cases. European Journal of Cancer, 31A, 1960-1964.
Boughey, J.C., Bedrosian, I., Meric-Bernstam, F., Ross, M.I., Kuerer, H.M., Akins, J.S., et al. (2006) Comparative Analysis of Sentinel Lymph Node Operation in Male and Female Breast Cancer Patients. Journal of the American College of Surgeons, 203, 475-480.
Albo, D., Ames, F.C., Hunt, K.K., Ross, M.I., Singletary, S.E. and Kuerer, H.M. (2003) Evaluation of Lymph Node Status in Male Breast Cancer Patients: A Role for Sentinel Lymph Node Biopsy. Breast Cancer Research and Treatment, 77, 9-14.
De Cicco, C., Baio, S.M., Veronesi, P., Trifiro, G., Ciprian, A., Vento, A., et al. (2004) Sentinel Node Biopsy in Male Breast Cancer. Nuclear Medicine Communications, 25, 139-143.
Macdonald, G., Paltiel, C., Olivotto, I.A. and Tyldesley, S. (2005) A Comparative Analysis of Radiotherapy Use and Patient Outcome in Males and Females with Breast Cancer. Annals of Oncology, 16, 1442-1448.
Lenfant-Pejovic, M.H., Mlika-Cabanne, N., Bouchardy, C., et al. (1990) Risk Factors for Male Breast Cancer: A Franco-Swiss Case-Control Study. International Journal of Cancer, 45, 661-665.
Perkins, G.H., Middleton, L.P., Garcia, S.M., Strom, E.A., McNeese, M.D., Singletary, S.E., et al. (2002) Male Breast Carcinoma: Out-Comes and Predictors of Local-Regional Failure in Patients Treated without Radiation Therapy. Breast Cancer Research and Treatment, 76, 121.
Bagley, C.S., Wesley, M.N., Young, R.C., et al. (1987) Adjuvant Chemotherapy in Males with Cancer of the Breast. American Journal of Clinical Oncology, 10, 55-60.
Galea, M.H., Blamey, R.W., Elston, C.E. and Ellis, I.O. (1992) The Nottingham Prognostic Index in Primary Breast Cancer. Breast Cancer Research and Treatment, 22, 207-219.
Ghersi, D., Wilcken, N. and Simes, R.J. (2005) A Systematic Review of Taxane-Containing Regimens for Metastatic Breast Cancer. British Journal of Cancer, 93, 293-301.
Fogh, S., Hirsch, A.E., Langmead, J.P., Goldberg, S.I., Rosenberg, C.L., Taghian, A.G., et al. (2011) Use of Tamoxifen with Postsurgical Irradiation May Improve Survival in Estrogen and Progesterone Receptor-Positive Male Breast Cancer. Clinical Breast Cancer, 11, 39-45.
Bourhafour, M., Belbaraka, R., Souadka, A., M’rabti, H., Tijami, F. and Errihani, H. (2011) Male Breast Cancer: A Report of 127 Cases at a Moroccan Institution. BMC Research Notes, 4, 219.
Italiano, A., Largillier, A., Marcy, P.Y., Foa, C., Forrero, J.M., Hartmann, M.T., et al. (2004) Complete Remission Obtained with Letrozole in a Man with Metastatic Breast Cancer. La Revue de Médecine Interne, 25, 323-324.
Labrie, F., Dupont, A., Belanger, A., Lacourciere, Y., Beland, L., Cusan, L., et al. (1990) Complete Response to Combination Therapy with an LHRH Agonist and Flutamide in Metastatic Male Breast Cancer: A Case Report. Clinical & Investigative Medicine, 13, 275-278.
Ballatore, Z., Pistelli, M., Battelli, N., Pagliacci, A., De Lisa, M., Berardi, R., et al. (2016) Everolimus and Exemestane in Long Survival Hormone Receptor Positive Male Breast Cancer: Case Report. BMC Research Notes, 9, 497.
Manso, L., Palomo, A.G., Pérez Carrión, R., Cassinello, J., Gallegos Sancho, I., Chacón, L.-M., et al. (2015) Factors Associated with the Selection of First-Line Bevacizumab plus Chemotherapy and Clinical Response in HER2-Negative Metastatic Breast Cancer: Oncosur Avalox Study. Anticancer Research, 35, 6941-6950.
Liu, D., Xie, G. and Chen, M. (2014) Clinicopathologic Characteristics and Survival of Male Breast Cancer. International Journal of Clinical Oncology, 19, 280-287.
Salvadori, B., Saccozzi, R., Manzari, A., Andreola, S., Conti, R.A., Cusumano, F., et al. (1994) Prognosis of Breast Cancer in Males: An Analysis of 170 Cases. European Journal of Cancer, 30A, 930-935.
Cutuli, B., Le Nir, C.C., Serin, D., Kirova, Y., Gaci, Z., Lemanski, C., et al. (2010) Male Breast Cancer. Evolution of Treatment and Prognostic Factors. Analysis of 489 Cases. Critical Reviews in Oncology/Hematology, 73, 246-254.
Soliman, A.A., Denewer, A.T., El-Sadda, W., Abdel-Aty, A.H. and Refky, B. (2014) A Retrospective Analysis of Survival and Prognostic Factors of Male Breast Cancer from a Single Center. BMC Cancer, 14, 227.
Arslan, U.Y., Oksuzoglu, B., Ozdemir, N., Aksoy, S., Alkis, N., Gok, A., et al. (2012) Outcome of Non-Metastatic Male Breast Cancer: 118 Patients. Medical Oncology, 29, 554-560.